Cargando…

Droxidopa for neurogenic orthostatic hypotension: A randomized, placebo-controlled, phase 3 trial

OBJECTIVE: To determine whether droxidopa, an oral norepinephrine precursor, improves symptomatic neurogenic orthostatic hypotension (nOH). METHODS: Patients with symptomatic nOH due to Parkinson disease, multiple system atrophy, pure autonomic failure, or nondiabetic autonomic neuropathy underwent...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaufmann, Horacio, Freeman, Roy, Biaggioni, Italo, Low, Phillip, Pedder, Simon, Hewitt, L. Arthur, Mauney, Joe, Feirtag, Michael, Mathias, Christopher J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4115605/ https://www.ncbi.nlm.nih.gov/pubmed/24944260 http://dx.doi.org/10.1212/WNL.0000000000000615

Ejemplares similares

Randomized Withdrawal Study of Patients With Symptomatic Neurogenic Orthostatic Hypotension Responsive to Droxidopa
por: Biaggioni, Italo, et al.
Publicado: (2015)

Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension
por: Biaggioni, Italo, et al.
Publicado: (2017)

Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension
por: François, Clément, et al.
Publicado: (2019)

Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
por: Kaufmann, Horacio
Publicado: (2017)

2198 Cognitive and behavioral side effects in patients treated with droxidopa for neurogenic orthostatic hypotension
por: McDonell, Katherine, et al.
Publicado: (2018)

Use of droxidopa for the long-term treatment of neurogenic orthostatic hypotension
por: Raj, Satish R, et al.
Publicado: (2019)

Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension
por: François, Clément, et al.
Publicado: (2016)

Neurogenic orthostatic hypotension – management update and role of droxidopa
por: Vijayan, Joy, et al.
Publicado: (2015)

Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension
por: Hauser, Robert A., et al.
Publicado: (2016)

Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Goodman, Brent P., et al.
Publicado: (2017)

Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease
por: Claassen, Daniel, et al.
Publicado: (2017)

Droxidopa Persistence in Neurogenic Orthostatic Hypotension May Be Affected by Titration Approach
por: Amjad, Fahd, et al.
Publicado: (2021)

Ampreloxetine Versus Droxidopa in Neurogenic Orthostatic Hypotension: A Comparative Review
por: Hoxhaj, Pranvera, et al.
Publicado: (2023)

Characterization of the changes in supine blood pressure with long‐term use of droxidopa in patients with neurogenic orthostatic hypotension
por: Hewitt, L. Arthur, et al.
Publicado: (2021)

Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment
por: Hauser, Robert A., et al.
Publicado: (2022)

Safety and efficacy of ampreloxetine in symptomatic neurogenic orthostatic hypotension: a phase 2 trial
por: Kaufmann, Horacio, et al.
Publicado: (2021)

Neurogenic orthostatic hypotension in Parkinson’s disease: evaluation, management, and emerging role of droxidopa
por: Isaacson, Stuart H, et al.
Publicado: (2014)

The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension
por: Gibbons, Christopher H., et al.
Publicado: (2017)

Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease
por: Kremens, Daniel, et al.
Publicado: (2017)

Neurogenic orthostatic hypotension: the very basics
por: Kaufmann, Horacio, et al.
Publicado: (2017)

Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
por: Gupta, Fiona, et al.
Publicado: (2017)

Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy
por: Goodman, Brent P., et al.
Publicado: (2017)

Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension
por: Mehdirad, Ali, et al.
Publicado: (2017)

Erratum to: Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension
por: Gupta, Fiona, et al.
Publicado: (2017)

Long-Term Outcomes of Hyperadrenergic Orthostatic Hypotension
por: Castro, Robert Alexander, et al.
Publicado: (2023)

Psychometric validation of a patient-reported single-item assessment of ‘Good Day Bad Day’ in a neurogenic orthostatic hypotension population treated with droxidopa
por: François, Clément, et al.
Publicado: (2022)

Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus
por: Vernino, Steven, et al.
Publicado: (2017)

Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension
por: Vernino, Steven, et al.
Publicado: (2017)

Neurogenic Orthostatic Hypotension in Parkinson Disease: A Primer
por: Cutsforth-Gregory, Jeremy K., et al.
Publicado: (2019)

Droxidopa as an effective treatment for refractory neurogenic orthostatic hypotension and reflex bradycardia in amyloid light-chain amyloidosis: a case report
por: Ho, Annie H., et al.
Publicado: (2020)

Characterization of the symptoms of neurogenic orthostatic hypotension and their impact from a survey of patients and caregivers
por: Claassen, Daniel O., et al.
Publicado: (2018)

Neurogenic orthostatic hypotension: pathophysiology, evaluation, and management
por: Metzler, Manuela, et al.
Publicado: (2012)

A Call to Action: The Role of Healthcare Providers in Reducing the Burden Associated with Neurogenic Orthostatic Hypotension
por: Gibson, Jessie S., et al.
Publicado: (2020)

Neurogenic Orthostatic Hypotension: State of the Art and Therapeutic Strategies
por: Kalra, Dinesh K, et al.
Publicado: (2020)

Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
Publicado: (2020)

Efficacy of atomoxetine versus midodrine for neurogenic orthostatic hypotension
por: Byun, Jung‐Ick, et al.
Publicado: (2019)

Norepinephrine reuptake blockade to treat neurogenic orthostatic hypotension
por: Eisenhofer, Graeme, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of ampreloxetine, a novel, selective norepinephrine reuptake inhibitor, in symptomatic neurogenic orthostatic hypotension
por: Lo, Arthur, et al.
Publicado: (2021)

Fludrocortisone Is Associated With a Higher Risk of All‐Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic Hypotension
por: Grijalva, Carlos G., et al.
Publicado: (2017)

Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient with Cardiovascular Disease and Parkinson's Disease
por: McCullough, Peter A.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_coagto6d6vb2dmm9gk9j083b8a